Pfizer has lined up as much as $1.5 billion from Blackstone to help pay for the late-stage testing of berobenatide, an experimental once-a-month weight-loss injection the drugmaker hopes will let it compete with the obesity drugs already sold by Eli Lilly and Novo Nordisk.
The deal, announced Wednesday, Nov. 11, is an unusual way to fund a big drug program. Blackstone Life Sciences will cover development costs through 2028. In return, it can collect milestone payments if U.S. regulators approve monthly dosing of berobenatide for chronic weight management and if the drug reaches certain sales targets, according to Reuters. Blackstone gets no ownership of the drug, and Pfizer keeps full control of the program. The size of the milestone payments was not disclosed.
What Pfizer is testing
Berobenatide is a GLP-1 drug, the same broad class as the popular weight-loss and diabetes shots that have reshaped the drug industry. What sets it apart, Pfizer says, is the goal of dosing it once a month instead of once a week.
In June, Pfizer reported mid-stage (Phase 2b) results showing people in one part of its VESPER-1 study lost 15.9% of their body weight, not adjusted for placebo, after 32 weeks on a 2.4 mg weekly dose, with no plateau yet. The company said it saw low rates of stomach-related side effects and dropouts. Pfizer has said it plans 10 Phase 3 studies of the drug, including weekly dosing, monthly maintenance dosing and studies in conditions linked to obesity such as knee osteoarthritis and obstructive sleep apnea. Upstormed News recently covered a daily GLP-1 pill tested for sleep apnea, one sign of how quickly the field is widening.
Why Pfizer is sharing the bill
Pfizer got berobenatide when it bought obesity biotech Metsera in a deal worth up to $10 billion in November 2025, after a bidding fight with Novo Nordisk. Reuters noted that purchase came near the end of a buying spree meant to replace revenue lost as COVID-19 product sales faded and to offset patent expirations on key medicines.
Large Phase 3 programs are expensive, and outside funding lets Pfizer spread that cost. Pfizer said the arrangement gives it more room to invest across the rest of its pipeline. Its new chief financial officer, Cecile Guegan, described the goal as bringing new medicines to patients “while taking a disciplined approach,” Reuters reported.
For Blackstone, this is a familiar model. Nicholas Galakatos, global head of Blackstone Life Sciences, has described the firm’s strategy as funding “products, not companies,” according to Healthcare Digital. The unit has made similar deals before, including up to $750 million for Moderna’s flu vaccine program announced in 2024 and a $400 million deal with Teva earlier this year. Pfizer and Blackstone also struck a smaller co-funding agreement in 2023.
A crowded and growing market
The obesity drug race keeps getting more competitive. On Thursday, Reuters reported that China approved Eli Lilly’s weight-loss pill orforglipron. J.P. Morgan research cited by Healthcare Digital estimates the global market for this family of drugs could reach $200 billion by 2030.
Investors took the Pfizer news calmly. Pfizer shares closed slightly higher at $29.45 on Wednesday and edged up 0.2% after hours, Reuters said. The broader market backdrop has been driven largely by tech and AI news this week, as Upstormed News reported in its look at Wednesday’s stock rebound.
Why it matters for families
- More choices could come, but not soon. Berobenatide is still in testing and is not approved. Any approval would depend on Phase 3 results and a review by the Food and Drug Administration.
- Monthly dosing is the selling point. If it works, fewer shots could make treatment easier to stick with. That is still a goal, not a proven result.
- Competition may matter for prices. More drugmakers in the market could add pressure on costs over time, though no one can say yet how prices or insurance coverage will change. Families already watching rising health insurance costs for 2027 may want to check how their plans handle weight-loss drugs.
- Talk with your doctor. Anyone considering a weight-loss medicine should discuss options and side effects with a health professional.
What to watch next
The next milestones are Phase 3 results from Pfizer’s VESPER program, more detail on how the Blackstone payments are structured, and whether rivals answer with their own monthly or oral options. Upstormed News will follow the story. This article is general news and not investment advice.
Read more: Stocks Rebound as CoreWeave Results Revive AI Trade
Would a once-a-month shot change how you think about weight-loss treatment? Tell us in the comments.
Sources: Reuters via Investing.com, “Pfizer secures up to $1.5 billion from Blackstone for obesity drug development” (November 11, 2026); Healthcare Digital, “Pfizer & Blackstone Strike US$1.5bn GLP-1 Obesity Drug Deal” (November 12, 2026); Pfizer, “Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide” (June 6, 2026); Reuters via Investing.com, “China approves Eli Lilly’s weight loss pill orforglipron” (November 12, 2026)
Leave a Reply